Aclaris TherapeuticsACRS +1.73%38 Gross Margin % is 10.42% as of Mar. 2026, which is 63% below its 10-year median of 28.28. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 736 Biotechnology companies, Aclaris Therapeutics ranks worse than 90.22% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aclaris Therapeutics had a gross margin of 10.42% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Aclaris Therapeutics Gross Margin % Related Terms
Aclaris Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACRS vs RLMD, GYRE, SGP: Gross Margin % Comparison
For the Biotechnology subindustry, Aclaris Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aclaris Therapeutics (ACRS) has a Gross Margin % of 10.42% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Aclaris Therapeutics and its competitors. This is 63% below median its historical median of 28.28. Over the past decade, Aclaris Therapeutics' Gross Margin % has ranged from 4.07 to 59.80. According to the industry distribution chart, Aclaris Therapeutics ranks #664 out of 736 companies in the Biotechnology industry, placing it in the top 90.2%.
Is Aclaris Therapeutics' Gross Margin % too high?
Aclaris Therapeutics' current Gross Margin % of 10.42% is 63% below median its 10-year median of 28.28. Over the past 10 years, this metric has ranged from a low of 4.07 to a high of 59.80. The Biotechnology industry median Gross Margin % is 60.91. Aclaris Therapeutics' value of 10.42% is 82.9% below this industry median. Based on the distribution chart, Aclaris Therapeutics ranks #664 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Gross Margin % compare to RLMD and GYRE?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #664 out of 736 companies for Gross Margin %. This places Aclaris Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. Aclaris Therapeutics' value of 10.42% is 82.9% below this benchmark. Historically, Aclaris Therapeutics' own Gross Margin % has ranged from 4.07 to 59.80 over the past decade. While the company's 10-year median is 28.28 vs. the industry median of 60.91, Aclaris Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclaris Therapeutics's current Gross Margin % of 10.42% is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Aclaris Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current Gross Margin % is 10.42%, which is 63% below median its own 10-year median of 28.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.00 — trading 1011.1% above its estimated fair value. The current Gross Margin % is 10.42%, which is 63% below median its 10-year median of 28.28 and 82.9% below the Biotechnology industry median of 60.91. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Gross Margin % is 10.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (ACRS) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of $5.00 is trading 1011.1% above its estimated GF Value™ of $0.45.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for ACRS:
Gross Margin %: 10.42% (63% below median its 10-year median of 28.28)
GF Value™: $0.45 vs. price of $5.00 (1011.1% above fair value)
Industry Position: 82.9% below the Biotechnology median (#664 of 736)
No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score
Get the complete analysis for ACRS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRS has been successfully added to your 
